ABSTRACT
Aim: Purpose of this study was to know which one is better modality of treatment for osteoporosis in postmenopausal women – enhancing bone formation or reducing bone resorption. Methods: Total 120 patients were included in this study and randomly divided in two groups. Group A patients were given teriparatide injection and Group B patients were given alendronate sodium tablet. Both groups were given Calcium supplement, and vitamin D supplement along with therapy. Bone mineral density (BMD) at the spine and hip was assessed by dual-energy x-ray absorptiometry (DEXA) scan before and after the therapy. Results: Average Bone mineral density (BMD) in teriparatide group was - 2.77 in pretreatment and – 1.8767 after one year follow up. Average BMD in alendronate sodium group was -2.78 in pretreatment and – 2.00 after one year follow up. Avearage gain in BMD in Group A was – 0.8933 and in group B was –0.78. Conclusion: Teriparatide seems to be better treatment for oeteoporosis as compared to alendronate therapy.